Limitations of MIC as Sole Metric of Pharmacodynamic Response Across the Range of Antimicrobial Susceptibilities within a Single Bacterial Species Publication Limitations of MIC as Sole Metric of Pharmacodynamic Response Across the Range of Antimicrobial Susceptibilities within a Single Bacterial Species The minimum inhibitory concentration (MIC) of an antimicrobial drug for a bacterial pathogen is used…Certara2016 年 12 月 1 日
Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage Publication Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage Certara2016 年 12 月 1 日
Quantifying Gut Wall Metabolism: Methodology Matters Publication Quantifying Gut Wall Metabolism: Methodology Matters Certara2016 年 12 月 1 日
Pharmacokinetics of Oral Terbinafine in Adult Horses Publication Pharmacokinetics of Oral Terbinafine in Adult Horses The primary study objective was to compare the pharmacokinetics of p.o. terbinafine alone to p.o.…Certara2016 年 11 月 24 日
Vaccination Mitigates the Impact of PRRSv Infection on the Pharmacokinetics of Ceftiofur Crystalline-free Acid in Pigs Publication Vaccination Mitigates the Impact of PRRSv Infection on the Pharmacokinetics of Ceftiofur Crystalline-free Acid in Pigs The pharmacokinetics of intramuscularly administered ceftiofur crystalline-free acid (CCFA) were determined in pigs that were…Certara2016 年 11 月 24 日
Early Assessment of Proarrhythmic Risk of Drugs Using the In Vitro Data and Single-cell-based In Silico Models: Proof of Concept Publication Early Assessment of Proarrhythmic Risk of Drugs Using the In Vitro Data and Single-cell-based In Silico Models: Proof of Concept Certara2016 年 11 月 23 日
A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics Publication A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics Certara2016 年 11 月 17 日
Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Publication Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Certara2016 年 11 月 15 日
IVIVC Software – Achieving Regulatory, Formulation and Manufacturing Success Brochure IVIVC Software – Achieving Regulatory, Formulation and Manufacturing Success In vitro-in vivo correlation (IVIVC) is an important, predictive mathematical tool in drug development, used…Certara2016 年 11 月 8 日
Modeling and Simulation Guides Dosing for a New Anti-psychotic Drug Blog Modeling and Simulation Guides Dosing for a New Anti-psychotic Drug Drug development is becoming more complex than ever. Regulatory agencies expect sponsors to consider a…Certara2016 年 10 月 21 日